You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KEYNOTE-192

Showing 1 - 25 of 214
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Cancer, Brain Tumor, Glioma Trial in Canada, United States (DNX-2401, pembrolizumab)

Completed
  • Brain Cancer
  • +10 more
  • DNX-2401
  • pembrolizumab
  • Little Rock, Arkansas
  • +14 more
Jul 13, 2021

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab, paclitaxel, docetaxel)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
May 5, 2022

NSCLC Trial (Pembrolizumab, Docetaxel)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 18, 2022

Small Cell Lung Cancer, SCLC Trial in Worldwide (Pembrolizumab, Normal saline solution, Carboplatin)

Completed
Has Results
  • Small Cell Lung Cancer (SCLC)
  • Pembrolizumab
  • +4 more
  • Miami, Florida
  • +147 more
Sep 2, 2022

Advanced Solid Tumor Trial in Beijing (ICP-192)

Recruiting
  • Advanced Solid Tumor
  • Bengbu, Anhui, China
  • +36 more
Jan 3, 2023

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

Intrahepatic Cholangiocarcinoma (ICC) Trial in China (ICP-192)

Recruiting
  • Intrahepatic Cholangiocarcinoma (ICC)
  • Hefei, Anhui, China
  • +43 more
Dec 23, 2022

Urinary Stone Trial in Madison (6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Tria ureteral stents)

Not yet recruiting
  • Urinary Stone
  • 6Fr Percuflex ureteral stents
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 9, 2023

Stage III/IV Melanoma Trial in Worldwide (tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse)

Recruiting
  • Stage III/IV Melanoma
  • tavokinogene telseplasmid
  • +2 more
  • Tucson, Arizona
  • +37 more
Dec 21, 2022

Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)

Active, not recruiting
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 17, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

Recruiting
  • Lung Cancer Stage III
  • Lung Cancer Stage IV
    • Brest, France
      Chu Brest
    Aug 16, 2023

    PFS, OS Trial in Qingdao (PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed)

    Recruiting
    • PFS
    • OS
    • PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
    • Qingdao, Shandong, China
      Qingdao central Hospital
    Feb 23, 2022

    Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

    Completed
    Has Results
    • Head and Neck Squamous Cell Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 24, 2022

    Bladder Urothelial Cancer Trial in China (ICP-192)

    Recruiting
    • Bladder Urothelial Cancer
    • Hefei, Anhui, China
    • +9 more
    Oct 20, 2021

    Emulation of KEYNOTE-189 Trial Using Electronic Health Records

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Metastatic Lung Cancer
    • Boston, Massachusetts
      Aetion
    Jun 14, 2023

    Tooth Loss, Vitamin D3 Deficiency, Osteomalacia Trial in Moscow (Dental implantation)

    Completed
    • Tooth Loss
    • +2 more
    • Dental implantation
    • Moscow, Russian Federation
    • +1 more
    Aug 10, 2022

    Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

    Recruiting
    • Advanced Non-squamous Non-Small-Cell Lung Cancer
    • Jinan, Shandong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Dec 4, 2022

    Insomnia Trial in Leiden (i-Sleep & BioClock, Online Psychoeducation)

    Not yet recruiting
    • Insomnia
    • i-Sleep & BioClock
    • Online Psychoeducation
    • Leiden, Netherlands
      Leiden Univeristy
    Sep 4, 2023

    Poliomyelitis Trial in Panama City (Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral

    Not yet recruiting
    • Poliomyelitis
    • Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)
    • Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)
    • Panama City, Panama
    • +3 more
    Dec 14, 2022

    Poliomyelitis Trial in Dhaka (Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral

    Not yet recruiting
    • Poliomyelitis
    • Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
    • Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
    • Dhaka, Bangladesh
      International Centre for Diarrhoeal Disease Research, Bangladesh
    Nov 30, 2022

    COVID-19, SARS CoV 2 Infection Trial in Australia (ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg))

    Not yet recruiting
    • COVID-19, SARS CoV 2 Infection
    • ChulaCov19 BNA159 vaccine (50 mcg)
    • Pfizer/BNT vaccine (30 mcg)
    • Bruce, Australian Capital Territory, Australia
    • +4 more
    Nov 15, 2022

    Urothelial Carcinoma Associated 1 RNA, Human Trial (Pembrolizumab, Cisplatin, Carboplatin)

    Active, not recruiting
    Has Results
    • Urothelial Carcinoma Associated 1 RNA, Human
    • Pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Cataract, Corneal Astigmatism Trial in United States (TECNIS® Toric II)

    Completed
    Has Results
    • Cataract
    • Corneal Astigmatism
    • TECNIS® Toric II
    • Bakersfield, California
    • +6 more
    May 5, 2022